About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Pharmacogenomics Studies of Antidepressants

NCT01204086·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

National Cheng-Kung University Hospital

With

Department of Health, Executive Yuan, R.O.C. (Taiwan)

Age

16–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age: 16-65 years old
Signed informed consent by patient or legal representative
Hamilton Rating Scale for Depression (HDRS) scores ≥ 16
A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry

You may not be if

monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study
A DSM-IV diagnosis of substance abuse within the past three months
An organic mental disease, mental retardation or dementia
A serious surgical condition or physical illness
Patients who were pregnant or breastfeeding

The record

StatusUnknown

PhasePhase 4

Taking part200

StartedMar 2007

UpdatedSep 17, 2010

Conditions

Major Depressive Disorder Antidepressive Agents Pharmacogenetics Venlafaxine Fluoxetine

Where1

National Cheng-Kung University Hospital
Tainan, Taiwan

Clareo Health | Pharmacogenomics Studies of Antidepressants